Article

Hydrophilic acrylic IOL affords novel delivery system to improve intraocular antibiotic concentrations

Results of a preclinical study undertaken at the John A. Moran Eye Center, University of Utah, Salt Lake City, indicate higher aqueous humor concentrations of fourth-generation fluoroquinolones can be achieved by implanting an antibiotic-presoaked IOL compared with standard topical administration, reported Guy Kleinmann, MD.

Results of a preclinical study undertaken at the John A. Moran Eye Center, University of Utah, Salt Lake City, indicate higher aqueous humor concentrations of fourth-generation fluoroquinolones can be achieved by implanting an antibiotic-presoaked IOL compared with standard topical administration, reported Guy Kleinmann, MD.

The study included two groups of 15 rabbits each. One group received a hydrophilic acrylic IOL (C-flex, Rayner) that had been presoaked for 24 hours in moxifloxacin 0.5% (Vigamox, Alcon Laboratories) or gatifloxacin 0.3% (Zymar, Allergan). The second group of animals received the standard IOL and was treated with topical antibiotic drops prior to and post-implantation using a typical cataract surgery prophylaxis protocol.

Aqueous humor samples were obtained at 4, 8, and 12 hours after implantation and antibiotic concentrations were analyzed with high performance liquid chromatography. The results showed that the antibiotic levels achieved after topical administration were consistent with those that have been reported previously in the literature.

However, with one exception, levels achieved with both antibiotics at all time periods were significantly higher in animals implanted with the antibiotic-soaked IOLs compared with after topical instillation. Slit-lamp examination performed 24 hours after implantation revealed no clinical signs of toxicity in any eyes.

"Recent reports indicate a gradual increase of postoperative endophthalmitis in the United States since 1992, and in response to significant increases in pathogen resistance to ciprofloxacin, cataract surgeons have switched to use of fourth-generation fluoroquinolones as endophthalmitis prophylaxis," Dr. Kleinmann said. "These results indicate this hydrophilic acrylic IOL can serve as an excellent drug delivery system to enhance achieved aqueous humor concentrations of the fourth-generation fluoroquinolones."

The study was supported by a grant from the American Society of Cataract and Refractive Surgery Foundation.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.